Your browser doesn't support javascript.
loading
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.
Brunner, P M; Conrad, C; Vender, R; Grond, S; Schuster, C; Patel, H; Xu, W; Carrascosa Carrillo, J M.
Affiliation
  • Brunner PM; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Conrad C; Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
  • Vender R; Dermatrials Research Inc, Hamilton, ON, Canada.
  • Grond S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Schuster C; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Patel H; Eli Lilly and Company, Indianapolis, IN, USA.
  • Xu W; Eli Lilly and Company, Indianapolis, IN, USA.
  • Carrascosa Carrillo JM; Eli Lilly and Company, Indianapolis, IN, USA.
Br J Dermatol ; 185(4): 865-867, 2021 10.
Article in En | MEDLINE | ID: mdl-34076896
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Dermatologic Agents Limits: Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article Affiliation country: Country of publication: